Lundbeck to restructure R&D, shedding up to 160 jobs

pharmafile | June 10, 2020 | News story | Manufacturing and Production, Research and Development Lundbeck, pharma, staff cuts 

Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research & Development operations – a move which may result in the culling of up to 160 staff.

The company says that this reorganisation will enable it to better “strengthen and advance” its neuroscience product pipeline across all phases of development.

Should the plan go ahead, it is expected that the move could result in the termination of between 130 and 160 members of staff, with around 100 of those cuts being made in Denmark. The company currently employs around 5,800 employees, and around 1,780 of these work in Denmark.

Johan Luthman, Executive Vice President of R&D at Lundbeck, commented on the plans: “The proposed changes will allow us to fully execute on our strategy in the years to come and rebuild our pipeline with innovative programs with strong potential to deliver highly impactful treatments for patients with brain disorders. Through this we will support Lundbeck in becoming the premier neuroscience company, globally.” 

While many companies have been forced to reorganise or downsize as a result of the ongoing COVID-19 pandemic, there was no indication that this move is an example of that. The plan forms part of Lundbeck’s Expand and Invest to Grow-strategy which aims to focus the company’s R&D operations on its most promising products, with particular emphasis placed on the efficacy of emerging technologies and flexibility of approach in making this a reality.

Matt Fellows

Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content